CBP-1008有望成为卵巢癌患者(无论FRα表达水平)未来更优的治疗选择。 A Phase 1, Multi-Center, Open-Label, Dose-Escalation and Dose Expansion Study of CBP-1018, a Bi-Ligand-Drug Conjugate in Patients with Heavily Treated Advanced Solid Tumors 这项1期研究包括剂量递增和扩展阶段,主要目的是评估安全...
标题:CBP-1018, a Bi-Ligand-Drug Conjugate treated in Patients with Advanced Solid Tumors: A Phase 1, Multi-Center, Open-Label, Dose-Escalation and Dose Expansion Study 壁报编号:1830P 报告专场:前列腺癌 研究设计: 本研究是一项I期多中心、开放标签、剂量爬坡和扩组研究,包括剂量递段和扩展研究两个...
⌈ByDrug医药新闻摘要⌋ 2024-06-12 09:58,同宜医药:近日,美国FDA基于对同宜医药CBP-1018单药的安全性,疗效以及临床药理等数据的审核,批准CBP-1018和恩扎卢胺联合用药的I/II期临床试验予以开展。 本联合用药Ⅰ/Ⅱ期临床试验申请获得FDA批准后,同宜医药将继续评估C
CBP-1018有望⽤于乳腺癌领域研究[1]。 REFERENCES [1].LiX,etal.LC-MS/MSmethodfordual-ligandpeptide-drugCBP-1018anditsdeconjugatedpayloadMMAEincludingsample stabilizationstrategyforitsMC-Val-Cit-PABClinker.Talanta.2024Nov1;279:126596. McePdfHeight Caution:Producthasnotbeenfullyvalidatedformedical...
摘要标题:CBP-1018双特异性配体偶联药物在晚期实体瘤患者的I期多中心、开放标签、剂量爬坡和扩组研究 (CBP-1018, a Bi-Ligand-Drug Conjugate treated in Patients with Advanced Solid Tumors: A Phase 1, Multi-Center, Open-Label, Dose-Escalation and Dose expansion Study ) ...
1602P CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study resultsdoi:10.1016/j.annonc.2024.08.1683K. LiJ. GuoJ. WuH. GuoH. HangJ. DaiL. Yang...
PD35-02CBP-1018, A DUAL-LIGAND DRUG TARGETING PSMA-FOLR1, IS AVAILABLE FOR PROSTATE CANCER TREATMENT AND HAS THE POTENTIAL TO BE USED IN COMBINATION WITH OTHER THERAPIESdoi:10.1097/01.JU.0001009396.21455.74.02Zhuang, RuilinHuang, HaiWolters KluwerJournal of Urology...